PMID- 26111471
OWN - NLM
STAT- MEDLINE
DCOM- 20151022
LR  - 20191008
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 52
IP  - 3
DP  - 2015 Jul
TI  - Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid 
      Leukemia.
PG  - 232-42
LID - S0037-1963(15)00029-3 [pii]
LID - 10.1053/j.seminhematol.2015.03.005 [doi]
AB  - Allogeneic hematopoietic cell transplantation (alloHCT) provides a potentially 
      curative therapy for patients with high-risk or chemorefractory acute myeloid 
      leukemia (AML). Historically, the applicability of alloHCT has been limited as 
      only 30%-35% of patients have human leukocyte antigen (HLA)-matched siblings and 
      outcomes using other donor types have been markedly inferior due to excess 
      toxicity, graft failure, graft-versus-host disease (GVHD), and consequently 
      non-relapse mortality. Advances in HLA typing, GVHD prophylactic approaches, and 
      other transplantation techniques have successfully addressed these historical 
      challenges. Herein, we review recent alloHCT studies using volunteer unrelated 
      donors, umbilical cord blood units, or HLA-haploidentical donors, specifically 
      focusing on studies that compared outcomes between donor sources. Although none 
      are randomized and most are retrospective, these analyses suggest that current 
      outcomes for AML patients using most alternative donor types are comparable to 
      those seen using HLA-matched siblings.
CI  - Published by Elsevier Inc.
FAU - Kanakry, Christopher G
AU  - Kanakry CG
AD  - Experimental Transplantation and Immunology Branch, National Cancer Institute, 
      National Institutes of Health, Bethesda, MD. Electronic address: 
      christopher.kanakry@nih.gov.
FAU - de Lima, Marcos J
AU  - de Lima MJ
AD  - University Hospitals Case Medical Center, Case Western Reserve University School 
      of Medicine, Cleveland, OH.
FAU - Luznik, Leo
AU  - Luznik L
AD  - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of 
      Medicine, Baltimore, MD.
LA  - eng
GR  - Z99 CA999999/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20150318
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
SB  - IM
MH  - Graft vs Host Disease/etiology
MH  - Haploidy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Histocompatibility Testing
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*therapy
MH  - Tissue Donors
MH  - Transplantation, Homologous
PMC - PMC4483196
MID - NIHMS687021
COIS- DISCLOSURES: The authors declare that they have no conflicts of interest or 
      competing financial or personal relationships that could inappropriately 
      influence the content of this article.
EDAT- 2015/06/27 06:00
MHDA- 2015/10/23 06:00
PMCR- 2016/07/01
CRDT- 2015/06/27 06:00
PHST- 2015/06/27 06:00 [entrez]
PHST- 2015/06/27 06:00 [pubmed]
PHST- 2015/10/23 06:00 [medline]
PHST- 2016/07/01 00:00 [pmc-release]
AID - S0037-1963(15)00029-3 [pii]
AID - 10.1053/j.seminhematol.2015.03.005 [doi]
PST - ppublish
SO  - Semin Hematol. 2015 Jul;52(3):232-42. doi: 10.1053/j.seminhematol.2015.03.005. 
      Epub 2015 Mar 18.